Egnyte Announces New Offering Providing Early-Stage Life Science Startups a Year of Egnyte’s Platform at No Cost

Egnyte the secure platform for content collaboration and governance, recently announced it will be providing early-stage life sciences innovators complimentary access to their award-winning Egnyte for Life Sciences platform. This offer is designed to accelerate “time to patient” for life sciences innovators and will give companies a full year of access to Egnyte’s platform to help them scale and optimize their business, collaborate across their partner ecosystems, and manage risk and regulatory compliance.

“More than ever, agility, speed and collaboration must become core competencies for every life sciences startup,” said Ronen Vengosh, vice president of Life Sciences at Egnyte. “Egnyte is proud to make our cloud-based data and document collaboration solutions even more widely available to the companies who are pioneering the next generation of treatments that will positively improve people’s lives.”

Also Read: Innovid To Present In Upcoming Investor Conferences

The Egnyte for Life Sciences platform enables pre-clinical and clinical-stage biotechs with limited IT resources to collaborate seamlessly on diverse data sets with their partner ecosystems, while maintaining the required levels of data control and compliance with industry regulations.

“Egnyte’s platform provides a reliable and secure collaboration environment that supports our current data management needs. It’s easy to use and can scale with us as our team grows,” said Joe Hunter, M.S., co-founder and co-CEO of VaxSyna. “As we proceed through pre-clinical trials and move to clinical trials, we have peace of mind knowing Egnyte’s cloud-based data and document collaboration platform meets regulatory requirements and will grow with us as we continue to focus on tackling global health challenges with our novel vaccine platform.”

 

SOURCE: PRWeb 

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More